Contract Assay Development
& Bioconjugation Services

Reader based multiplex lateral flow assays are opening new opportunities for biomarker signatures, structured data capture and algorithmic interpretation. This article explores how candidate markers can be assessed, translated into lateral flow and developed into reliable diagnostic systems with the reader, software, manufacture and regulatory pathway considered from the start.

Performance verification helps assay developers generate controlled, traceable evidence to support analytical performance claims, regulatory submissions and product launch. Fleet Bioprocessing provides CRO support for assay performance verification, claim support, study planning, protocol development, execution and reporting.

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

This article compares sandwich vs competitive assays in ELISA and lateral flow, focusing on format selection, reagent strategy and assay development considerations.

Performance verification is the stage at which a lateral flow assay moves from development understanding to formal analytical evidence. This article explains how intended use and design inputs shape verification strategy, how CLSI-guided studies are structured, and why robust documentation is critical for transfer, submission, and product readiness.

This guide to lateral flow assay development explains how to improve assay sensitivity and reproducibility through antibody screening, membrane selection, conjugate optimisation, strip design and process control.

In this article, we explore how sample type and matrix effects influence lateral flow assay (LFA) performance, going beyond initial antibody selection and detector optimisation. Real-world samples such as whole blood, saliva, urine, swab extracts, and environmental matrices introduce variability, chemical interference, and flow challenges that can significantly impact sensitivity, specificity, and reproducibility.

Just as careful antibody selection is critical for Lateral Flow Assay (LFA) performance, the choice of detector label and its conjugation strategy directly influences assay sensitivity, specificity, reproducibility and scalability. Detector labels convert binding events into measurable signals and the way these labels are prepared and evaluated has a profound impact on how reliably an assay performs. Gold nanoparticles have become the most widely used detector because of thei